HPS Pharmacies wish to advise that Merck Healthcare is anticipating a supply interruption for Cetrotide® as follows:

Cetrotide® Injection
Cetrorelix (as acetate) 250 microgram
ARTG 74888

A shortage of Cetrotide® is expected to occur at the end of August 2022 and last until the end of October 2022. This is due to technical problems at the main manufacturing site which has led to the reduced and delayed supply of Cetrotide®. The quality of the manufactured and released product batches is not affected by these technical issues.

HPS Pharmacies currently has access to a supply of Cetrotide® that has been restricted according to our historical usage. When supplies are exhausted, Merck Healthcare advises that alternative GnRH antagonists may be considered. Two brands of ganirelix are currently available, Orgalutran® and Ganirelix SUN.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Merck Healthcare on 1800 257 348 or your pharmacist at HPS Pharmacies.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates